Skip Navigation


Human Molecular Genetics Advance Access originally published online on October 6, 2005
Human Molecular Genetics 2005 14(22):3507-3521; doi:10.1093/hmg/ddi380
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
14/22/3507    most recent
ddi380v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by McCampbell, A.
Right arrow Articles by Brown, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCampbell, A.
Right arrow Articles by Brown, R. H., Jr
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy

Alexander McCampbell1,*, David Truong1, Daniel C. Broom3, Andrew Allchorne3, Ken Gable5, Roy G. Cutler7, Mark P. Mattson7, Clifford J. Woolf3, Matthew P. Frosch2,4, Jeffrey M. Harmon6, Teresa M. Dunn5 and Robert H. Brown, Jr1

1Day Laboratory for Neuromuscular Research, 2Alzheimer's Research Unit, Mass General Institute for Neurodegenerative Disease, 3Neural Plasticity Research Group, Department of Anesthesia and Critical Care, 4C.S. Kubik Laboratory for Neuropathology, Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA, 5Department of Biochemistry and Molecular Biology, 6Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD 20184-4799, USA and 7Laboratory of Neurosciences, National Institute on Ageing Intramural Research Program, Baltimore, MD 21224, USA

* To whom correspondence should be addressed. Tel: +1 6177245334; Fax: +1 6177248543; Email: amccampbell{at}partners.org

Received August 5, 2005; Accepted October 3, 2005

Mutations in enzymes involved in sphingolipid metabolism and trafficking cause a variety of neurological disorders, but details of the molecular pathophysiology remain obscure. SPTLC1 encodes one subunit of serine palmitoyltransferase (SPT), the rate-limiting enzyme in sphingolipid synthesis. Mutations in SPTLC1 cause hereditary sensory and autonomic neuropathy (type I) (HSAN1), an adult onset, autosomal dominant neuropathy. HSAN1 patients have reduced SPT activity. Expression of mutant SPTLC1 in yeast and mammalian cell cultures dominantly inhibits SPT activity. We created transgenic mouse lines that ubiquitously overexpress either wild-type (SPTLC1WT) or mutant SPTLC1 (SPTLC1C133W). We report here that SPTLC1C133W mice develop age-dependent weight loss and mild sensory and motor impairments. Aged SPTLC1C133W mice lose large myelinated axons in the ventral root of the spinal cord and demonstrate myelin thinning. There is also a loss of large myelinated axons in the dorsal roots, although the unmyelinated fibers are preserved. In the dorsal root ganglia, IB4 staining is diminished, whereas expression of the injury-induced transcription factor ATF3 is increased. These mice represent a novel mouse model of peripheral neuropathy and confirm the link between mutant SPT and neuronal dysfunction.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J BiochemHome page
H. Ikushiro, M. M. Islam, A. Okamoto, J. Hoseki, T. Murakawa, S. Fujii, I. Miyahara, and H. Hayashi
Structural Insights into the Enzymatic Mechanism of Serine Palmitoyltransferase from Sphingobacterium multivorum
J. Biochem., October 1, 2009; 146(4): 549 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. C. Raman, K. A. Johnson, B. A. Yard, J. Lowther, L. G. Carter, J. H. Naismith, and D. J. Campopiano
The External Aldimine Form of Serine Palmitoyltransferase: STRUCTURAL, KINETIC, AND SPECTROSCOPIC ANALYSIS OF THE WILD-TYPE ENZYME AND HSAN1 MUTANT MIMICS
J. Biol. Chem., June 19, 2009; 284(25): 17328 - 17339.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Han, S. D. Gupta, K. Gable, S. Niranjanakumari, P. Moitra, F. Eichler, R. H. Brown Jr., J. M. Harmon, and T. M. Dunn
Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities
PNAS, May 19, 2009; 106(20): 8186 - 8191.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
H. Ikushiro, M. M. Islam, H. Tojo, and H. Hayashi
Molecular Characterization of Membrane-Associated Soluble Serine Palmitoyltransferases from Sphingobacterium multivorum and Bdellovibrio stolpii
J. Bacteriol., August 1, 2007; 189(15): 5749 - 5761.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hornemann, S. Richard, M. F. Rutti, Y. Wei, and A. von Eckardstein
Cloning and Initial Characterization of a New Subunit for Mammalian Serine-palmitoyltransferase
J. Biol. Chem., December 8, 2006; 281(49): 37275 - 37281.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.